Showing results (321-330 of 832) with videos related to
Sort By:
Pageof 84
Nephron|October 9, 2023
Techniques to Assess the Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Blood Volume in Patients with Diabetic Kidney DiseaseVårin Vinje, Tobias Bomholt, Peter Rossing, et al.Circulation|December 28, 2006
Subclinical coronary and aortic atherosclerosis detected by magnetic resonance imaging in type 1 diabetes with and without diabetic nephropathyWon Yong Kim, Anne Sofie Astrup, Matthias Stuber, et al.Journal of the American Society of Nephrology : JASN|April 6, 2007
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trialWouter B A Eijkelkamp, Zhongxin Zhang, Giuseppe Remuzzi, et al.Kidney International|April 1, 2011
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal functionFrank A Holtkamp, Dick de Zeeuw, Merlin C Thomas, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 16, 2009
Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study designHans-Henrik Parving, Barry M Brenner, John J V McMurray, et al.Diabetes & Vascular Disease Research|October 20, 2022
Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosisElisabeth B Stougaard, Peter L Kristensen, Urd Kielgast, et al.European Journal of Endocrinology|January 6, 2011
Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetesLian Engelen, Søren S Lund, Isabel Ferreira, et al.Primary Care Diabetes|October 22, 2022
Biochemical profiling, pharmacological management and clinical outcomes in type 2 diabetes in Danish primary care from 2001 to 2015Niels Søndergaard Heinrich, Margit Kriegbaum, Mia Klinten Grand, et al.Clinical Journal of the American Society of Nephrology : CJASN|March 18, 2017
Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal FunctionSergei Petrykiv, C David Sjöström, Peter J Greasley, et al.Journal of the American Heart Association|June 20, 2019
Efficacy of Long-Term Remote Ischemic Conditioning on Vascular and Neuronal Function in Type 2 Diabetes Patients With Peripheral Arterial DiseaseChristian S Hansen, Marit E Jørgensen, Jesper Fleischer, et al.Pageof 84